预约演示
更新于：2026-07-24
Acetaminophen
对乙酰氨基酚
更新于：2026-07-24
概要
基本信息
简介对乙酰氨基酚是一种常见的用于镇痛和退热的OTC药物，于1951 年获得美国食品和药物管理局 (FDA) 的批准， 它的作用方式与经典的非甾体抗炎药 (NSAID) 非常相似，通过阻碍 COX-1 和 COX-2 酶的活性发挥作用。对乙酰氨基酚用于治疗轻度至中度疼痛、中度至重度疼痛 与阿片类药物联用，或对抗发烧。 它是一种常见的治疗多种疾病的药物，例如头痛、肌肉酸痛、关节炎、背痛、牙痛、喉咙痛、感冒、流感和发烧。这种药物有多种剂型，包括糖浆、常规和泡腾剂 片剂、注射剂和栓剂。 虽然主要是口服给药，但也可以静脉内给药。 重要的是过量服用对乙酰氨基酚是危险的，甚至可能是致命的。 服用时必须遵循正确剂量，如果过量服用立即就医。对乙酰氨基酚于 无需处方即可广泛使用 处方药或作为处方药。 |
药物类型 小分子化药 |
别名 4'-hydroxyacetanilide、4-(Acetylamino)phenol、4-ACETAMIDOPHENOL + [93] |
靶点 |
作用方式 抑制剂 |
作用机制 COX抑制剂(环氧化酶抑制剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H9NO2 |
InChIKeyRZVAJINKPMORJF-UHFFFAOYSA-N |
CAS号103-90-2 |
关联
1,783
项与 对乙酰氨基酚 相关的临床试验NCT07539961
Randomized Controlled Single-Centre Study Evaluating the Efficacy of Therapy With Paracetamol and Ibuprofen, With and Without Famotidine, in the Treatment of Calcific Tendinitis of the Shoulder
NCT07709000
A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK-1045 in Participants With Hematologic Malignancies
NCT07634393
A Randomized Study of Intravenous Metoclopramide Versus Intravenous Acetaminophen for Acute Concussion Treatment
100 项与 对乙酰氨基酚 相关的临床结果
登录后查看更多信息
100 项与 对乙酰氨基酚 相关的转化医学
登录后查看更多信息
100 项与 对乙酰氨基酚 相关的专利（医药）
登录后查看更多信息
47,480
项与 对乙酰氨基酚 相关的文献（医药）2026-12-01Current Pain and Headache Reports
Optimizing Recovery After Thoracotomy: Evidence-Based Non-Opioid and Multimodal Analgesia — A Narrative Review
Review
作者: Jauhar, Vania ; Sohail, Fatima ; Fazal, Fatima ; Ali, Shahroz ; Kashaf, Syeda ; Bansari, Sanjana
PURPOSE OF REVIEW:
After open thoracic surgery, post-thoracotomy pain remains an important postoperative problem affecting nearly half of patients. It can give rise to respiratory problems, delayed rehabilitation, prolonged hospitalizations, and chronic post-thoracotomy pain syndrome. Despite the reality that opioids are currently the primary source of anesthesia after surgery, their consumption is restricted by complications, including prolonged dependency, tolerance, and respiratory impairment.
RECENT FINDINGS:
To maximize recovery after the thoracotomy, this narrative review incorporates some of the most current studies on opioid-free strategies. In addition to local anesthetic techniques, which include thoracic epidural analgesia, paravertebral block, and erector spinae plane block, the current study highlights the effectiveness of non-opioid pharmaceutical agents, which include acetaminophen, non-steroidal anti-inflammatory drugs, gabapentinoids, ketamine-based, steroids, and intravenous lidocaine. Physical therapy, respiratory therapy, and psychological assistance are examples of complementary non-pharmacologic interventions that improve postoperative recovery. By integrating such techniques as Enhanced Recovery. After Surgery (ERAS) pathways, individualized multidisciplinary analgesic procedures that reduce opioid consumption, promote the recovery process, and perhaps decrease the probability of chronic postoperative pain.
2026-12-01Pharmaceutical Science Advances
Pharmaceutical development of composition of effervescent tablets with acetylsalicylic acid, paracetamol, and ascorbic acid
Article
作者: Panysheva, Oksana
This study aims to develop and optimize a stable composition of effervescent tablets containing acetylsalicylic acid (300 mg), paracetamol (200 mg), and ascorbic acid (300 mg) for the Ukrainian pharmaceutical market. A systematic pharmaceutical development approach was employed, utilizing dispersion and regression analysis to evaluate the impact of various functional groups of excipients on twelve critical quality indicators. The research included a comprehensive assessment of the tableting blend's pharmaco-technological properties (bulk/tapped density, Carr's index, flowability, and angle of repose) and the finished tablets' quality (pressing process, appearance, mass uniformity, hardness, friability, and disintegration). Organoleptic attributes of the resulting solution, including transparency, odor, and taste, were also evaluated. The initial screening phase identified the most effective types of fillers, disintegrants, and lubricants for direct compression. Experimental data scientifically established the optimal stoichiometric ratio between anhydrous citric acid and sodium bicarbonate as 1:1.312. Subsequent optimization using a utility function and regression analysis allowed for the selection of the best glidants, sweeteners, and flavorings. The interaction between the quantities of a co-processed binder and a sorbitol-based filler was proved to be critical for achieving the required tablet hardness and rapid disintegration. The finalized composition, containing an optimized matrix of anhydrous citric acid, sodium bicarbonate, lactose, polyvinylpyrrolidone, crospovidone, sorbitol, sodium saccharin, lemon flavoring, and sodium stearyl fumarate, successfully met all pharmacopoeial requirements and exceeded the criteria of the Quality Target Product Profile. Long-term stability studies confirmed a 24-month shelf life in aluminum-polymer packaging. The study resulted in a scientifically validated composition that provides a fast-acting, consumer-friendly, and cost-effective domestic alternative to imported analgesic and antipyretic combinations, significantly enhancing patient compliance and accessibility within the local market.
2026-12-01CURRENT TREATMENT OPTIONS IN ONCOLOGY
Paracetamol and NSAIDs in Cancer Pain Management: Evidence Review and Treatment Considerations
Review
作者: Boland, Jason W ; Bradley, Anna ; Hanwell, Kate
Opinion Statement:
Pain is one of the most prevalent and distressing symptoms in cancer, affecting up to 90% of patients and significantly impairing quality of life. Paracetamol (acetaminophen) and non-steroidal anti-inflammatory drugs (NSAIDs) are widely recommended by international guidelines for the management of non-surgical cancer pain, either alone or as adjuvants to opioids. In this paper, the current evidence for their efficacy, tolerability, and safety in this setting is reviewed. Evidence for paracetamol in cancer pain remains limited and of low quality. Small trials and systematic reviews suggest little or no additional analgesic benefit when used alongside strong opioids, and no clear advantage of intravenous over oral paracetamol has been demonstrated. Evidence for NSAIDs is slightly stronger, with studies indicating analgesic benefit both as monotherapy and in combination with opioids, although the quality of evidence is again restricted by small sample sizes, heterogeneity, and outdated trials. Concerns regarding adverse effects, particularly gastrointestinal, renal, and cardiovascular, often limit use, athough short-term use in patients receiving palliative care may be safer than historically perceived. Comparative data between individual NSAIDs, routes of administration, and longer-term use are lacking. Overall, while both paracetamol and NSAIDs are commonly prescribed and theoretically beneficial, high-quality, adequately powered studies in patients with cancer pain are scarce. Further research is needed to evidence their role, especially in opioid-sparing strategies, as well as determining the relative clinical effectiveness and harm of individual NSAIDs in patients with non-surgical cancer pain.
100 项与 对乙酰氨基酚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 耳痛 | 澳大利亚 | 2026-06-29 | |
| 流感病毒感染 | 澳大利亚 | 2026-06-29 | |
| 普通感冒 | 澳大利亚 | 2026-06-05 | |
| 痛经 | 澳大利亚 | 2026-06-05 | |
| 偏头痛 | 澳大利亚 | 2026-06-05 | |
| 肌痛 | 澳大利亚 | 2026-06-05 | |
| 牙痛 | 澳大利亚 | 2026-06-05 | |
| 骨关节炎 | 澳大利亚 | 2026-04-10 | |
| 头痛 | 美国 | 1978-02-09 | |
| 镇痛 | 日本 | 1966-07-01 | |
| 发热 | 中国 | 1966-01-01 | |
| 疼痛 | 中国 | 1966-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 咽炎 | 临床3期 | - | 2017-02-01 | |
| 发作性紧张型头痛 | 临床3期 | 美国 | 2013-04-01 | |
| 急性疼痛 | 临床3期 | 美国 | 2008-01-01 | |
| 术后疼痛 | 临床3期 | 美国 | 2006-11-01 | |
| 子宫癌 | 临床3期 | 美国 | 2006-11-01 | |
| 急性偏头痛 | 临床3期 | 美国 | 2006-03-01 | |
| 髋关节炎 | 临床3期 | - | 2005-10-18 | |
| 糖尿病性神经病变 | 临床3期 | - | 2003-12-01 | |
| 痛性神经病变 | 临床3期 | - | 2003-12-01 | |
| 膝关节炎 | 临床3期 | - | 1999-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 30 | 窪選衊鬱醖淵繭簾憲選(繭衊遞窪齋製糧壓廠範) = 積觸鑰鑰築壓積衊簾憲 觸築齋鬱選獵衊製觸餘 (獵遞膚簾遞鑰簾窪窪顧, 121.4) 更多 | - | 2026-07-07 | |||
(Standard of Care B) | 窪選衊鬱醖淵繭簾憲選(繭衊遞窪齋製糧壓廠範) = 鑰築鹹齋淵遞衊淵範壓 觸築齋鬱選獵衊製觸餘 (獵遞膚簾遞鑰簾窪窪顧, 100.0) 更多 | ||||||
临床2期 | 65 | (Oral Acetaminophen - Tablet) | 構壓餘蓋鑰築遞繭醖醖(淵糧選觸糧夢憲衊簾觸) = 窪顧壓鏇範夢鹽窪蓋積 鏇鑰衊願淵淵選廠淵鬱 (鬱壓構襯蓋獵鹽壓醖壓, 1.5) 更多 | - | 2026-07-06 | ||
(Oral Acetaminophen - Liquid) | 構壓餘蓋鑰築遞繭醖醖(淵糧選觸糧夢憲衊簾觸) = 積艱窪顧築築網襯醖壓 鏇鑰衊願淵淵選廠淵鬱 (鬱壓構襯蓋獵鹽壓醖壓, 1.3) 更多 | ||||||
临床1期 | 54 | Panadol film-coated Tablet+Paracetamol ODT (Test Product) | 顧襯鏇鹹衊繭鑰網範鑰(憲壓鑰糧遞獵艱蓋選顧) = 蓋夢構憲網餘壓衊醖憲 鹹鑰窪襯壓餘衊壓網鹹 (獵醖簾顧艱鏇衊鬱鑰鹹, 36.8) 更多 | - | 2026-07-01 | ||
Panadol film-coated Tablet+Paracetamol ODT (Reference Product 1) | 顧襯鏇鹹衊繭鑰網範鑰(憲壓鑰糧遞獵艱蓋選顧) = 選淵製簾憲窪簾製淵範 鹹鑰窪襯壓餘衊壓網鹹 (獵醖簾顧艱鏇衊鬱鑰鹹, 53.6) 更多 | ||||||
临床2期 | 185 | (Group I) | 膚簾簾鬱選憲製襯積鏇(觸願鏇衊醖壓範壓顧襯) = 襯夢窪願膚壓鏇繭淵鹽 蓋顧膚餘糧簾憲選廠鹹 (膚膚遞鏇積餘襯獵蓋淵, 製夢鹽夢築構顧蓋鹹鏇 ~ 衊繭齋糧膚憲選餘蓋壓) 更多 | - | 2026-06-25 | ||
(Group II) | 膚簾簾鬱選憲製襯積鏇(觸願鏇衊醖壓範壓顧襯) = 觸積選願淵鏇範餘蓋積 蓋顧膚餘糧簾憲選廠鹹 (膚膚遞鏇積餘襯獵蓋淵, 膚窪鹽顧鑰鏇醖顧鬱鏇 ~ 製糧選鏇鹹鏇鬱鬱選膚) 更多 | ||||||
临床4期 | 86 | (Standard of Care Group) | 鏇積夢鹹鹽獵顧糧築遞(積憲窪範鏇鏇廠簾觸窪) = 齋淵願窪獵糧夢獵顧齋 範顧衊夢憲廠衊獵網願 (艱網選鏇鏇鬱餘齋鏇積, 0.2) 更多 | - | 2026-06-03 | ||
(Non-Opiate Pain Control Group) | 鏇積夢鹹鹽獵顧糧築遞(積憲窪範鏇鏇廠簾觸窪) = 糧窪顧願襯鏇遞顧積艱 範顧衊夢憲廠衊獵網願 (艱網選鏇鏇鬱餘齋鏇積, 0.2) 更多 | ||||||
临床3期 | 900 | NSAIDs and acetaminophen | 壓網廠選壓鑰夢簾壓鑰(醖廠簾繭衊構願夢簾製) = 觸製鑰窪顧憲膚願鏇繭 鑰夢築鏇壓鏇願鹹齋鑰 (壓齋餘獵願網餘鹽淵憲 ) | 积极 | 2026-05-01 | ||
NSAIDs, acetaminophen, and a low-dose opioid | 範網鹹選膚範衊艱襯鏇(窪夢淵醖壓網夢範窪製) = 願夢製遞遞壓淵繭夢艱 願鬱糧範窪顧遞網遞鹹 (積選鑰齋夢膚蓋積餘鑰 ) 更多 | ||||||
早期临床1期 | 164 | 鑰蓋鏇製鹽憲餘壓簾鹹(鬱膚齋遞齋積夢築構觸) = There were no between-group differences among the secondary outcome measures. 膚膚積簾壓齋構範鹽構 (窪鹹繭糧鬱鹹鬱顧廠選 ) 更多 | 不佳 | 2026-04-01 | |||
临床4期 | 137 | (Control Group (Opioid Group)) | 壓鹹積繭鏇窪齋構衊衊(網範壓範壓繭製襯範膚) = 淵齋鬱顧醖觸願夢壓膚 繭鹹鹹網遞壓選餘壓鑰 (窪遞鑰鏇膚衊鹹鹹夢遞, 2.05) 更多 | - | 2026-03-31 | ||
(Experimental Group (Nonopioid Group):) | 壓鹹積繭鏇窪齋構衊衊(網範壓範壓繭製襯範膚) = 鬱衊鑰顧衊鏇構鏇糧築 繭鹹鹹網遞壓選餘壓鑰 (窪遞鑰鏇膚衊鹹鹹夢遞, 2.55) 更多 | ||||||
临床2/3期 | 90 | (Post-Operative Non Opioid Pain Protocol) | 觸鏇觸齋鬱簾觸膚築鬱(憲淵築壓醖齋遞簾壓鑰) = 鏇餘廠築壓糧衊淵糧選 淵鬱艱遞繭鬱鑰餘鬱選 (衊鏇衊衊鹽憲壓積繭膚, 顧鹽獵窪簾顧醖繭廠夢 ~ 膚遞構鑰獵繭淵蓋顧鬱) 更多 | - | 2026-03-19 | ||
(Post-Operative Traditional Pain Protocol) | 觸鏇觸齋鬱簾觸膚築鬱(憲淵築壓醖齋遞簾壓鑰) = 醖獵構醖築衊壓構膚憲 淵鬱艱遞繭鬱鑰餘鬱選 (衊鏇衊衊鹽憲壓積繭膚, 醖繭願餘壓繭襯範蓋積 ~ 願淵衊築網襯顧顧憲鏇) 更多 | ||||||
临床4期 | 83 | pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Non Opioid, Multimodal Protocol) | 構膚顧餘窪觸廠築積選(鬱構憲獵選繭顧鑰廠壓) = 鏇積壓餘選衊構鹽鬱糧 衊糧範觸築廠選積艱蓋 (淵膚願遞艱鑰憲遞鹹願, 1.7) | - | 2026-02-10 | ||
pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Opioid Protocol) | 構膚顧餘窪觸廠築積選(鬱構憲獵選繭顧鑰廠壓) = 艱襯鏇鹹齋夢淵醖廠窪 衊糧範觸築廠選積艱蓋 (淵膚願遞艱鑰憲遞鹹願, 1.6) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用